# DIAGNOS Inc. Type: Company (DGNOF) Source: GetYourBrief — https://getyourbrief.com/entity/diagnos-inc Canonical HTML page: https://getyourbrief.com/entity/diagnos-inc ## Timeline - **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws. - **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws. - **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws. - **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws. - **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash. - **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash. - **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash. - **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash. - **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance. - **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance. - **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance. - **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance. - **2026-02-26**: Market Reporting — Financial news outlets and analysts begin reporting on the company's performance. - **2026-02-25**: Earnings Release — DIAGNOS Inc. issues financial results for the latest fiscal period. - **2026-Q1**: Strategic Expansion — Ongoing rollout of the CARA platform in international markets including Saudi Arabia and Mexico. ## Recent coverage (5 stories, network-wide) ### How DIAGNOS Converted C$125K Debt into Equity at C$0.20 to Extend Runway 2026-06-21 00:12:03 · Sector: startups · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Startup DIAGNOS, building AI eye diagnostics, used a shares-for-debt settlement to preserve cash and extend its operating runway. The deal adds 625,000 shares at C$0.20 each, showing how early-stage companies can renegotiate obligations to survive. Full story: https://getstartupbrief.com/story/diagnos-startup-cash-management-debt-equity ### DIAGNOS Dilutes Equity: 625K Shares Issued at C$0.20 to Settle C$125K Debt 2026-06-21 00:11:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4 DIAGNOS announces a C$125K debt settlement through issuance of common shares at C$0.20, a move that conserves cash but dilutes existing shareholders. The transaction awaits TSX Venture approval and introduces a four-month hold period. Full story: https://getfinancebrief.com/story/diagnos-adk-debt-settlement-dilution ### DIAGNOS Converts C$125K Debt into 625K Shares at C$0.20 to Secure AI Diagnostic Pipeline 2026-06-21 00:11:46 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Biotech company DIAGNOS executes a small debt-for-equity swap, preserving liquidity to sustain its AI-based early detection platform for critical eye conditions. The move reflects the tight capital environment for early-stage diagnostic innovators. Full story: https://getbiobrief.com/story/diagnos-debt-equity-biotech-cash ### DIAGNOS Preserves Cash with C$125K Debt-for-Equity at C$0.20 to Fuel AI Eye Diagnostics 2026-06-21 00:10:37 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Diagnos Inc. converts C$125K in debt to equity, preserving cash to further develop its AI-powered early detection of eye-related health issues. The move underscores the financial pressures on health AI startups but keeps the clinical mission on track. Full story: https://gethealthbrief.com/story/diagnos-cash-preservation-ai-eye-diagnostics ### DIAGNOS (DGNOF) Reports Earnings Amid Expanding AI Retinal Screening Demand 2026-02-26 17:30:55 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 DIAGNOS Inc. (OTCMKTS: DGNOF) has released its latest financial results, highlighting the company's ongoing efforts to scale its AI-driven retinal screening platform. The results come as the healthcare industry increasingly adopts automated diagnostic tools to address the global rise in diabetic retinopathy and other vision-threatening conditions. Full story: https://gethealthbrief.com/story/diagnos-dgnof-earnings-ai-retinal-screening --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.